Volume 89, Issue 4
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



The investigation of gender-specific partitioning of the antimalarial drug mefloquine to cellular and fluid blood compartments was performed using blood collected from a female and male healthy subject that were infected with PCM2 clone and spiked with mefloquine (0.25, 1, and 5 μM). Mefloquine concentrations in red cells of both female and male subjects were significantly higher than plasma, which suggests an intensive uptake by red cells. This was supported by a high ratio of mefloquine concentrations in the parasitized and non-parasitized red cells of about 4-fold. Gender-specific partitioning of mefloquine in parasitized blood was seen only in plasma where significantly higher concentrations were observed in female compared with male plasma. Down-adjusting the therapeutic dose of mefloquine in female patients with malaria is not advisable because mefloquine concentrations in the target cellular compartment are similar in both genders.


Article metrics loading...

Loading full text...

Full text loading...



  1. World Health Organization (WHO), 2011. World Malaria Report. Geneva: World Health Organization.
  2. World Health Organization (WHO), 2010. Guidelines for the Treatment of Malaria. Second edition. Geneva: World Health Organization.
  3. Congpuong K, Bualombai P, Banmairuroi V, Na-Bangchang K, , 2010. Compliance with a three-day course of artesunate-mefloquine combination and baseline anti-malarial treatment in an area of Thailand with highly multidrug resistant falciparum malaria. Malar J 9: 43.[Crossref]
  4. Karbwang J, White NJ, , 1990. Clinical pharmacokinetics of mefloquine. Clin Pharmacokinet 19: 264279.[Crossref]
  5. Stürchler D, Handschin J, Kaiser D, Kerr L, Mittelholzer ML, Reber R, Fernex M, , 1991. Neuropsychiatric side effects of mefloquine. N Engl J Med 322: 17521753.
  6. Phillips-Howard P, ter Kuile F, , 1995. CNS adverse events associated with antimalarial agents. Drug Saf 12: 370383.[Crossref]
  7. Barrett PJ, Emmins PD, Clarke PD, Bradley DJ, , 1996. Comparison of adverse effects associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travelers. BMJ 313: 525528.[Crossref]
  8. Croft A, World M, , 1996. Neuropsychiatric reactions with mefloquine chemoprophylaxis. Lancet 347: 326335.[Crossref]
  9. van Riemsdijk MM, van der Klauw MM, van Heest JA, Reedeker FR, Ligthelm RJ, Herings RM, Stricker BH, , 1997. Neuro-psychiatric effects of anti-malarials. Eur J Clin Pharmacol 52: 16.[Crossref]
  10. Rønn AM, Ronne-Rasmussen J, Gotzsche PC, Bygbjerg IC, , 1998. Neuropsychiatric manifestations after mefloquine therapy for Plasmodium falciparum malaria: comparing a retrospective and a prospective study. Trop Med Int Health 3: 8388.[Crossref]
  11. Lim LY, Go ML, , 1985. The anticholinesterase activity of mefloquine. Clin Exp Pharmacol Physiol 12: 527531.[Crossref]
  12. Schwartz E, Potasman I, Rotenberg M, Almog S, Sadetzki S, , 2001. Serious adverse events of mefloquine in relation to blood level and gender. Am J Trop Med Hyg 65: 189192.
  13. Hennequin C, Bourée P, Bazin N, Bisaro F, Feline A, , 1994. Severe psychiatric side effects observed during prophylaxis and treatment with mefloquine. Arch Intern Med 154: 23602362.[Crossref]
  14. Jasper CA, Hopperus Buma AP, van Thiel PP, van Hulst RA, Kager PA, , 1996. Tolerance of mefloquine chemoprophylaxis in Dutch military tolerance personnel. Am J Trop Med Hyg 55: 230234.
  15. Schlagenhauf P, Steffen R, Lobel H, Johnson R, Letz R, Tschopp A, Vranjes N, Bergqvist Y, Ericsson O, Hellgren U, Rombo L, Mannino S, Handschin J, Stürchler D, , 1996. Mefloquine tolerability during chemoprophylaxis: focus on adverse event assessment, stereochemistry and compliance. Trop Med Int Health 1: 485494.[Crossref]
  16. Phillip M, , 1996. Adverse events associated with mefloquine: women may be more susceptible to adverse events. BMJ 313: 15521553.[Crossref]
  17. Kollaritsch H, Karbwang J, Wiedermann G, Mikolasek A, Na-Bangchang K, Wernsdorfer WH, , 2000. Mefloquine concentration profiles during prophylactic dose regimens. Wien Klin Wochenschr 112: 441447.
  18. Rendi-Wagner P, Noedl H, Wernsdorfer WH, Wiedermann G, Mikolasek A, Kollaritsch H, , 2002. Unexpected frequency, duration, and spectrum of adverse events after therapeutic dose of mefloquine in healthy adults. Acta Trop 8: 167173.[Crossref]
  19. Foley M, Tilley L, , 1998. Quinoline antimalarials: mechanisms of action and resistance and prospects for new agents. Pharmacol Ther 79: 5587.[Crossref]
  20. Trager W, Jensen JB, , 1976. Human malaria parasites in continuous culture. Science 193: 673675.[Crossref]
  21. Lambros C, Vanderberg JP, , 1979. Synchronization of Plasmodium falciparum erythrocytic stages in culture. J Parasitol 65: 418420.[Crossref]
  22. Karbwang J, Molunto P, Na Bangchang K, Bunnag D, , 1989. Determination of mefloquine in biological fluids using high performance liquid chromatography. Southeast Asian J Trop Med Public Health 20: 5560.
  23. Na-Bangchang K, Ruengweerayut R, Wernsdorfer WH, , 2011. Distribution of mefloquine in the blood of Thai patients with acute uncomplicated falciparum malaria following administration of therapeutic doses of artesunate. Eur J Clin Pharmacol 67: 687691.[Crossref]
  24. Weidekamm E, Rüsing G, Caplain H, Sörgel F, Crevoisier C, , 1998. Lack of bioequivalence of a generic mefloquine tablet with the standard product. Eur J Clin Pharmacol 54: 615619.[Crossref]
  25. Na-Bangchang K, Karbwang J, Palacios PA, Ubalee R, Saengtertsilapachai S, Wernsdorfer WH, , 2000. Pharmacokinetics and bioequivalence evaluation of three commercial tablet formulations of mefloquine when given in combination with dihydroartemisinin in patients with acute uncomplicated falciparum malaria. Eur J Clin Pharmacol 55: 743748.[Crossref]
  26. Palmer KJ, Holliday SM, Brogden RN, , 1993. Mefloquine a review of its antimalarial activity. Drug 45: 430475.[Crossref]
  27. Karbwang J, Back DJ, Bunnag D, Breckenridge AM, , 1988. A comparison of the pharmacokinetics of mefloquine in healthy Thai volunteers and in Thai patients with falciparum malaria. Eur J Clin Pharmacol 35: 677680.[Crossref]
  28. Fitch CD, Chan RL, Chevli R, , 1979. Chloroquine resistance in malaria: accessibility of drug receptors to mefloquine. Antimicrob Agents Chemother 15: 248262.[Crossref]
  29. San George RC, Nagel RL, Farby ME, , 1984. On the mechanism of the red-cell accumulation of mefloquine, and antimalarial drug. Biochim Biophys Acta 803: 174181.[Crossref]
  30. Chevil R, Fitch CD, , 1992. The antimalarial drug mefloquine binds to membrane phospholipids. Antimicrob Agents Chemother 21: 581586.[Crossref]
  31. Weinke T, Trautmann M, Held T, Weber G, Eichenlaub D, Fleischer K, Kern W, Pohle HD, , 1991. Neuropsychiatric side effects after the use of mefloquine. Am J Trop Med Hyg 45: 8691.
  32. McIntosh HM, Olliaro P, , 2006. Artemisinin derivatives for treating uncomplicated malaria. Cochrane Database Syst Rev 2.
  33. ter Kuile FC, Luxemburger F, Nosten L, Phaipun T, Chongsuphajaisiddhi T, White NJ, , 1995. Predictors of mefloquine treatment failure: a prospective study in 1590 patients with uncomplicated falciparum malaria. Trans R Soc Trop Med Hyg 89: 660664.[Crossref]

Data & Media loading...

  • Received : 05 Jun 2013
  • Accepted : 27 Jul 2013

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error